BURLINGTON, Mass., Feb. 28, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc., (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, today announced positive results from the Phase 1 clinical trial of TSO (Trichuris suis ova or CNDO-201) in patients with Crohn’s disease. The study showed that TSO is safe and well tolerated. TSO, the microscopic eggs of the pig whipworm, is a novel, orally administered, natural immunomodulator that regulates T-Cells and inflammatory cytokines.
